Sign In
Buy DNA
Ginkgo Bioworks Earnings Calls
| Release date | May 07, 2026 |
| EPS estimate | -$1.21 |
| EPS actual | -$1.39 |
| EPS Surprise | -14.77% |
| Revenue estimate | 42.928M |
| Revenue actual | 19.474M |
| Revenue Surprise | -54.64% |
| Release date | Feb 26, 2026 |
| EPS estimate | -$1.80 |
| EPS actual | -$1.42 |
| EPS Surprise | 21.11% |
| Revenue estimate | 37.092M |
| Revenue actual | 33M |
| Revenue Surprise | -11.03% |
| Release date | Nov 06, 2025 |
| EPS estimate | -$1.24 |
| EPS actual | -$1.45 |
| EPS Surprise | -16.94% |
| Revenue estimate | 37.568M |
| Revenue actual | 38.837M |
| Revenue Surprise | 3.38% |
| Release date | Aug 07, 2025 |
| EPS estimate | -$1.44 |
| EPS actual | -$1.10 |
| EPS Surprise | 23.61% |
| Revenue estimate | 38.945M |
| Revenue actual | 49.604M |
| Revenue Surprise | 27.37% |
Last 4 Quarters for Ginkgo Bioworks
Below you can see how DNA performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Aug 07, 2025 |
| Price on release | $13.46 |
| EPS estimate | -$1.44 |
| EPS actual | -$1.10 |
| EPS surprise | 23.61% |
| Date | Price |
|---|---|
| Aug 01, 2025 | $12.19 |
| Aug 04, 2025 | $13.60 |
| Aug 05, 2025 | $14.28 |
| Aug 06, 2025 | $13.96 |
| Aug 07, 2025 | $13.46 |
| Aug 08, 2025 | $12.29 |
| Aug 11, 2025 | $11.89 |
| Aug 12, 2025 | $11.56 |
| Aug 13, 2025 | $13.26 |
| 4 days before | 10.42% |
| 4 days after | -1.49% |
| On release day | -8.69% |
| Change in period | 8.78% |
| Release date | Nov 06, 2025 |
| Price on release | $11.30 |
| EPS estimate | -$1.24 |
| EPS actual | -$1.45 |
| EPS surprise | -16.94% |
| Date | Price |
|---|---|
| Oct 31, 2025 | $12.99 |
| Nov 03, 2025 | $12.79 |
| Nov 04, 2025 | $11.59 |
| Nov 05, 2025 | $11.59 |
| Nov 06, 2025 | $11.30 |
| Nov 07, 2025 | $8.95 |
| Nov 10, 2025 | $8.77 |
| Nov 11, 2025 | $8.46 |
| Nov 12, 2025 | $8.36 |
| 4 days before | -13.01% |
| 4 days after | -26.02% |
| On release day | -20.80% |
| Change in period | -35.64% |
| Release date | Feb 26, 2026 |
| Price on release | $9.71 |
| EPS estimate | -$1.80 |
| EPS actual | -$1.42 |
| EPS surprise | 21.11% |
| Date | Price |
|---|---|
| Feb 20, 2026 | $9.22 |
| Feb 23, 2026 | $8.86 |
| Feb 24, 2026 | $8.86 |
| Feb 25, 2026 | $9.38 |
| Feb 26, 2026 | $9.71 |
| Feb 27, 2026 | $6.75 |
| Mar 02, 2026 | $7.05 |
| Mar 03, 2026 | $6.70 |
| Mar 04, 2026 | $6.69 |
| 4 days before | 5.31% |
| 4 days after | -31.10% |
| On release day | -30.48% |
| Change in period | -27.44% |
| Release date | May 07, 2026 |
| Price on release | $10.32 |
| EPS estimate | -$1.21 |
| EPS actual | -$1.39 |
| EPS surprise | -14.77% |
| Date | Price |
|---|---|
| May 01, 2026 | $9.70 |
| May 04, 2026 | $9.91 |
| May 05, 2026 | $9.71 |
| May 06, 2026 | $10.08 |
| May 07, 2026 | $10.32 |
| May 08, 2026 | $8.93 |
| May 11, 2026 | $8.67 |
| May 12, 2026 | $8.34 |
| May 13, 2026 | $8.59 |
| 4 days before | 6.39% |
| 4 days after | -16.76% |
| On release day | -13.47% |
| Change in period | -11.44% |
Ginkgo Bioworks Earnings Call Transcript Summary of Q1 2026
Ginkgo is positioning itself to lead the emerging category of autonomous labs, centering 2026 investments on scaling its Nebula autonomous lab in Boston and selling systems to early adopters (e.g., Pacific Northwest National Labs). The company completed the spin-off of its biosecurity business (Perimeter), reporting it as discontinued operations, and ended Q1 2026 with $373M cash and no bank debt. Q1 continuing-operations revenue was $19M (down 49% YoY, or down 37% excluding a prior noncash item); R&D and G&A fell ~38% and ~35% YoY respectively due to restructuring. Adjusted EBITDA was negative $42M and net loss from continuing operations was $76M. Cash burn in Q1 was $48M; management reaffirmed full-year 2026 cash-burn guidance of $125M–$150M. Strategic highlights: Nebula now runs 24/7, is being scaled to ~100+ rack carts (103–105 racks imminent), has run 100+ protocols with 30+ unique protocols and hundreds of scientist users, and demonstrated an OpenAI project where GPT-5-driven experiment design improved a cell-free protein synthesis metric by ~40% over state-of-the-art. Commercial initiatives include the Cloud Lab (cloud.ginkgo.bio) and partnerships/channels with AWS (Amazon Biodiscovery), Benchling, and Tamarind Bio, plus continued traction for DataPoints (10 top pharma customers) and a $47M contract with PNNL for a large autonomous lab deployment. Management emphasizes cost discipline while investing in AI, robotics, software, and customer deployments to convert lab-bench work to automated/cloud workflows.
